Molecular responses to immune checkpoint blockade in glioblastoma

Hirotaka Ito; Hiroshi Nakashima; E Antonio Chiocca

doi:10.1038/s41591-019-0385-7

Molecular responses to immune checkpoint blockade in glioblastoma

Nat Med. 2019 Mar;25(3):359-361. doi: 10.1038/s41591-019-0385-7.

Authors

Hirotaka Ito¹, Hiroshi Nakashima¹, E Antonio Chiocca²

Affiliations

¹ Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. eachiocca@bwh.harvard.edu.

Abstract

Transcriptional signatures and immune cell infiltrates associated with immune activation distinguish patients with glioblastoma who initially respond to immune checkpoint blockade from those who do not.

Publication types

Comment

MeSH terms

Adult
Glioblastoma / immunology*
Humans
Immunotherapy
Neoadjuvant Therapy
Nivolumab
Programmed Cell Death 1 Receptor

Substances

Programmed Cell Death 1 Receptor
Nivolumab

Abstract

Publication types

MeSH terms

Substances

Grants and funding